Disclaimer: This site aggregates publicly available data from official government sources (FDA, ClinicalTrials.gov, PubMed, SEC EDGAR, NMPA) for general reference only. It does NOT constitute medical advice, diagnosis, treatment recommendations, or investment advice.

Clinical Trial

Evaluation of Nasal Biomarkers for Objective Assessment of Disease Severity in Respiratory Disorders

NCT: NCT06661252 · COMPLETED

NCT IDNCT06661252
StatusCOMPLETED
Start Date2025-01-08
Completion2025-11-25

Brief Summary

This research study is an observational, single site study quantifying expression of biomarkers of respiratory disease in nasal fluid using the ABEL microsampler device. The primary objective of this study is to compare biomarker expression between healthy controls and participants with respiratory disorders such as chronic obstructive pulmonary disorder (COPD), hayfever, chronic sinusitis, asthma and rhinitis.

Frequently Asked Questions

What is Evaluation of Nasal Biomarkers for Objective Assessment of Disease Severity in Respiratory Disorders?

Evaluation of Nasal Biomarkers for Objective Assessment of Disease Severity in Respiratory Disorders is a clinical trial registered under NCT06661252. Current status: COMPLETED.

What is the status of NCT06661252?

The current status of NCT06661252 (Evaluation of Nasal Biomarkers for Objective Assessment of Disease Severity in Respiratory Disorders) is: COMPLETED.

When did Evaluation of Nasal Biomarkers for Objective Assessment of Disease Severity in Respiratory Disorders start?

Evaluation of Nasal Biomarkers for Objective Assessment of Disease Severity in Respiratory Disorders started on 2025-01-08.

Official Source

View on ClinicalTrials.gov →

Data sourced from ClinicalTrials.gov API. For the most current status, refer to the official record.

↑